A meta-analysis of efficacy and safety of doripenem for treating bacterial infections
Objective: The aim of this article is to compare the efficacy and safety of doripenem for bacterial infections. Methods: We included six randomized clinical trials identified from PubMed and Embase up to July 31, 2014. The included trials compared efficacy and safety of doripenem for complicated int...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2015-03-01
|
| Series: | Brazilian Journal of Infectious Diseases |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1413867015000227 |
| _version_ | 1818250417084039168 |
|---|---|
| author | Xiao-Yu Qu Ting-Ting Hu Wei Zhou |
| author_facet | Xiao-Yu Qu Ting-Ting Hu Wei Zhou |
| author_sort | Xiao-Yu Qu |
| collection | DOAJ |
| description | Objective: The aim of this article is to compare the efficacy and safety of doripenem for bacterial infections. Methods: We included six randomized clinical trials identified from PubMed and Embase up to July 31, 2014. The included trials compared efficacy and safety of doripenem for complicated intra-abdominal infections, complicated urinary tract infection, nosocomial pneumonia, and acute biliary tract infection. The meta-analysis was carried on by the statistical software of Review Manager, version 5.2. Results: Compared with empirical antimicrobial agents on overall treatment efficacy, doripenem was associated with similar clinical and microbiological treatment success rates (for the clinical evaluable population, odds ratio [OR] = 1.26, 95% confidence interval [CI] 0.93–1.69, p = 0.13; for clinical modified intent-to-treatment population, OR = 0.88, 95% CI 0.55–1.41, p = 0.60; for microbiology evaluable population, OR = 1.16, 95% CI 0.90–1.50, p = 0.26; for microbiological modified intent-to-treatment (m-mITT), OR = 0.98, 95% CI 0.81–1.20, p = 0.87). We compared incidence of adverse events and all-cause mortality to analyze treatment safety. The outcomes suggested that doripenem was similar to comparators in terms of incidence of adverse events and all-cause mortality on modified intent-to-treatment population (for incidence of AEs, OR = 1.10, 95% CI 0.90–1.35, p = 0.33; for all-cause mortality, OR = 1.08, 95% CI 0.77–1.51, p = 0.67). In nosocomial pneumonia and ventilator-associated pneumonia treatment, doripenem was not inferior to other antibacterial agents in terms of efficacy and safety. Conclusion: From this meta-analysis, we can conclude that doripenem is as valuable and well-tolerated than empirical antimicrobial agents for complicated intra-abdominal infections, complicated urinary tract infection, acute biliary tract infection and nosocomial pneumonia treatment. Keywords: Doripenem, Meta-analysis, Efficacy, Safety, Infection |
| first_indexed | 2024-12-12T15:52:03Z |
| format | Article |
| id | doaj.art-1eb528fc43f34eb5a8961c73e0dd3501 |
| institution | Directory Open Access Journal |
| issn | 1413-8670 |
| language | English |
| last_indexed | 2024-12-12T15:52:03Z |
| publishDate | 2015-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Brazilian Journal of Infectious Diseases |
| spelling | doaj.art-1eb528fc43f34eb5a8961c73e0dd35012022-12-22T00:19:36ZengElsevierBrazilian Journal of Infectious Diseases1413-86702015-03-01192156162S1413-86702015000200156A meta-analysis of efficacy and safety of doripenem for treating bacterial infectionsXiao-Yu Qu0Ting-Ting Hu1Wei Zhou2Department of Pharmacy, The First Hospital of Jilin University, Changchun 130021, PR China; Corresponding author at: Xinmin Street 71#, Changchun City, PR China.Department of Technical Center, Jilin Entry Exit Inspection and Quarantine Bureau, Changchun 130062, PR ChinaDepartment of Pharmacy, The First Hospital of Jilin University, Changchun 130021, PR ChinaObjective: The aim of this article is to compare the efficacy and safety of doripenem for bacterial infections. Methods: We included six randomized clinical trials identified from PubMed and Embase up to July 31, 2014. The included trials compared efficacy and safety of doripenem for complicated intra-abdominal infections, complicated urinary tract infection, nosocomial pneumonia, and acute biliary tract infection. The meta-analysis was carried on by the statistical software of Review Manager, version 5.2. Results: Compared with empirical antimicrobial agents on overall treatment efficacy, doripenem was associated with similar clinical and microbiological treatment success rates (for the clinical evaluable population, odds ratio [OR] = 1.26, 95% confidence interval [CI] 0.93–1.69, p = 0.13; for clinical modified intent-to-treatment population, OR = 0.88, 95% CI 0.55–1.41, p = 0.60; for microbiology evaluable population, OR = 1.16, 95% CI 0.90–1.50, p = 0.26; for microbiological modified intent-to-treatment (m-mITT), OR = 0.98, 95% CI 0.81–1.20, p = 0.87). We compared incidence of adverse events and all-cause mortality to analyze treatment safety. The outcomes suggested that doripenem was similar to comparators in terms of incidence of adverse events and all-cause mortality on modified intent-to-treatment population (for incidence of AEs, OR = 1.10, 95% CI 0.90–1.35, p = 0.33; for all-cause mortality, OR = 1.08, 95% CI 0.77–1.51, p = 0.67). In nosocomial pneumonia and ventilator-associated pneumonia treatment, doripenem was not inferior to other antibacterial agents in terms of efficacy and safety. Conclusion: From this meta-analysis, we can conclude that doripenem is as valuable and well-tolerated than empirical antimicrobial agents for complicated intra-abdominal infections, complicated urinary tract infection, acute biliary tract infection and nosocomial pneumonia treatment. Keywords: Doripenem, Meta-analysis, Efficacy, Safety, Infectionhttp://www.sciencedirect.com/science/article/pii/S1413867015000227 |
| spellingShingle | Xiao-Yu Qu Ting-Ting Hu Wei Zhou A meta-analysis of efficacy and safety of doripenem for treating bacterial infections Brazilian Journal of Infectious Diseases |
| title | A meta-analysis of efficacy and safety of doripenem for treating bacterial infections |
| title_full | A meta-analysis of efficacy and safety of doripenem for treating bacterial infections |
| title_fullStr | A meta-analysis of efficacy and safety of doripenem for treating bacterial infections |
| title_full_unstemmed | A meta-analysis of efficacy and safety of doripenem for treating bacterial infections |
| title_short | A meta-analysis of efficacy and safety of doripenem for treating bacterial infections |
| title_sort | meta analysis of efficacy and safety of doripenem for treating bacterial infections |
| url | http://www.sciencedirect.com/science/article/pii/S1413867015000227 |
| work_keys_str_mv | AT xiaoyuqu ametaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections AT tingtinghu ametaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections AT weizhou ametaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections AT xiaoyuqu metaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections AT tingtinghu metaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections AT weizhou metaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections |